==== Front Kardiochir Torakochirurgia PolKardiochir Torakochirurgia PolKITPKardiochirurgia i Torakochirurgia Polska = Polish Journal of Cardio-Thoracic Surgery1731-55301897-4252Termedia Publishing House 3306410.5114/kitp.2018.76477Review PaperDel Nido cardioplegia – what is the current evidence? Sanetra Krzysztof 1Pawlak Ireneusz 1Cisowski Marek 121 1st Department of Cardiac Surgery, Centre for Cardiovascular Research and Development, American Heart of Poland, Bielsko-Biala, Poland2 Department of Cardiac, Vascular and Endovascular Surgery and Transplantology in Zabrze, Medical University of Silesia in Katowice, PolandAddress for correspondence: Krzysztof Sanetra, 1st Department of Cardiac Surgery, Centre for Cardiovascular Research and Development, American Heart of Poland, 101 Armii Karajowej St, 43-316 Bielsko-Biala, Poland. phone: +48 692 030 003. e-mail: krzyssan@poczta.onet.pl25 6 2018 6 2018 15 2 114 118 04 1 2018 12 1 2018 Copyright: © 2018 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska)2018This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.Del Nido cardioplegia is believed to be both clinically and economically efficient. The interest in this myocardial protection method has been continuously growing. However, the evidence is not clear. The article summarizes recent reports regarding del Nido cardioplegia. Streszczenie Kardioplegina del Nido jest uznawana za roztwór o dużej skuteczności klinicznej, który zapewnia optymalną efektywność kosztową. Wydaje się, że ciągle wzrasta zainteresowanie jej stosowaniem. Dotychczasowe badania nie są jednak jednoznaczne. W artykule przedstawiono ostatnie doniesienia dotyczące stosowania kardiopleginy del Nido. del Nidocardioplegia ==== Body Introduction Cardiac surgery procedures usually involve the use of cardiopulmonary bypass and cardiac arrest. In consequence, myocardial protection is essential. Inadequate protection may cause myocardial stunning, cell apoptosis and infarction. The search for an ideal cardioplegic solution has continued since the very beginning of cardiac surgery. Plenty of solutions are available, both commercial and self-made. Yet, there are no guidelines referring to use of a specific solution, and the literature does not clearly confirm the superiority of one over another. Mechanism of myocardial injury The understanding of ischemia-reperfusion injury by practicing cardiac surgeons plays the key role in the myocardial protection strategy and may be one of the main determinants of clinical outcome. The damage is induced while the heart is arrested. However, it is aggravated during the reperfusion (the “ischemia-reperfusion injury”). Free oxygen radicals and calcium ions are the most important factors determining the injury progression [1, 2]. Cessation of the oxygen supply has its consequence in a loss of ATP production and an increase of reactive oxygen species in the mitochondria. The Na+–K+-pump’s activity is strictly related to ATP availability. Its dysfunction leads to Na+ accumulation in the cell. In consequence, the membrane potential is lowered. The anaerobic metabolism for ATP production proceeds, resulting in gathering of hydrogen ions and lactate, which decreases anaerobic glycolysis. As acidosis progresses, the Na+–H+ exchanger leads to further intracellular Na+ accumulation. The 3 Na+–1 Ca2+ exchanger function deteriorates because of the Na+ increase. It may work in the reverse mode as well. Both mechanisms lead to intracellular Ca2+ gathering. The other mechanism of intracellular Ca2+ accumulation is its release from the sarcolemmal L-type voltage-gated Ca2+ channel (L) as a consequence of lowering the resting membrane potential. Furthermore, the mitochondrial calcium uptake is damaged due to ischemic depolarization and impaired recovery of membrane potential during reperfusion. The Na+–K+ pump recovers slowly due to ATP production in the reperfusion process. The reoxygenation triggers reactive oxygen species formation. Moreover, an elevated level of Ca2+ in this early phase of reperfusion, when compensatory mechanisms are not efficient, causes myocardial hypercontracture and severe myocardial damage. The Ca2+ ions are currently believed to be the most important factor in ischemia-reperfusion injury [3]. The cardioplegia concept In 1950 Bigelow et al. opened the pathway for further development of surgical myocardial protection by describing the application of deep hypothermia in canines [4]. Three years later Melrose et al. introduced the concept of chemical cardiac arrest in canines [5]. Gerbode and Melrose were the first to report use of potassium citrate to induce cardiac arrest in humans [6]. The project relied on the assumption that a high concentration of potassium ions depolarizes the membrane and arrests the heart in diastole. This publication began the era of cardioplegia. In general, two types of cardioplegia are described: Cold crystalloid cardioplegic solutions They contain potassium concentration in the range between 10 and 40 mmol/l (mEq/l) and usually have high buffering capability (bicarbonate). There are various types of solutions, both commercial and self-made. They may be further divided into two types. – Intracellular type – typically characterized by absent or low concentrations of sodium and calcium. – Extracellular type – typically characterized by higher concentrations of sodium, calcium and magnesium. Blood cardioplegia – Cold blood cardioplegia – probably the most widely used solution across the globe. There are various formulations. Autologous blood from the cardiopulmonary circuit is obtained and mixed with crystalloid solution. A high concentration of potassium (> 30 mEq/l) is used for arresting the heart. Potential additives include, for example, citrate-phosphate-dextrose (CPD), tris-hydroxymethyl aminomethane (THAM) or bicarbonate. The most common blood : crystalloid ratio is 4 : 1 or 8 : 1. The delivery temperature is 4–12°C. – Warm blood cardioplegia – usually delivered additionally to another cardioprotective method as a “hot shot” (single administration just before declamping the aorta), which is intended to improve myocardial recovery. – Tepid blood cardioplegia – originally described as 29°C cardioplegia. In some studies, it revealed excellent capabilities in reducing anaerobic lactate acid release [7]. Its role has not been confirmed in a large, multicenter study. Del Nido cardioplegia Del Nido cardioplegia was developed by Pedro Del Nido and his team at the University of Pittsburgh in 1990s. It has been used for pediatric cardiac surgery in Boston’s Children Hospital since 1994 and, since 2003, it has been successfully used for adult cardiac surgery as well [8]. The cardioplegia solution itself is an extracellular solution mixed with autologous blood obtained from the extracorporeal circuit. The crystalloid : blood ratio is 4 : 1. One dose of 20 ml/kg is calculated to obtain optimal myocardial protection for 90 min. The administration pressure is 100–200 mm Hg and the administration flow is 200–300 ml/min. The potassium concentration is > 25 mEq/l. The achieved myocardial temperature is < 15°C. The crystalloid solution includes Plasma-Lyte as a basic solution, mannitol, magnesium sulfate, bicarbonate, potassium and lidocaine (Table I). Some ingredients have a different concentration and volume when distributed in Europe, so the formula needs to be modified (as seen in Table II) to obtain the same ingredient concentration in the solution. Table I The del Nido cardioplegia solution as described originally Ingredient Volume [ml] Role Plasma-Lyte A 1000 Basic solution (Na 140 mmol/l; K 5 mmol/l; Mg 3 mmol/l; pH 7.4) Mannitol 20% 16.3 Osmotic pressure, free-radical scavenger MgSO4 50% 4 Calcium channel blocker, improved myocardial recovery NaHCO3 8.4% 13 pH buffer KCl 2 mEq/l 13 Myocardial depolarization Lidocaine 1% 13 Sodium channel blocker, hyperpolarizing agent Table II The del Nido cardioplegia solution – calculated for European products Ingredient Volume [ml] Role Plasma-Lyte A 1000 Basic solution (Na 140 mmol/l; K 5 mmol/l; Mg 3 mmol/l; pH 7.4) Mannitol 15% 20 Osmotic pressure, free-radical scavenger MgSO4 20% 10 Calcium channel blocker, improved myocardial recovery NaHCO3 1 mEq/ml 13 pH buffer KCl 2 mEq/l 13 Myocardial depolarization Lidocaine 2% 6.5 Sodium channel blocker, hyperpolarizing agent Each ingredient plays an important role in the cardioprotection strategy. Plasma-Lyte A is a commercial solution. It contains 140 mEq/l sodium, 5 mEq/l potassium, 3 mEq/l magnesium, 98 mEq/l chloride, 27 mEq/l acetate and 23 mEq/l gluconate. The pH is 7.4. Mannitol has capabilities of both scavenging free radicals and reducing edema due to its hyperosmotic capabilities [9]. Magnesium additive blocks the calcium channels [10], which has proved to improve myocardial recovery [11, 12]. Sodium bicarbonate scavenges hydrogen ions and maintains intracellular pH. Potassium chloride provides rapid depolarized arrest. However, research associates sole depolarized arrest with impaired myocardial recovery due to intracellular sodium and calcium accumulation [13]. The potassium concentration in the del Nido cardioplegia solution is 24 mEq/l. Lidocaine is a sodium channel blocker and class Ib antiarrhythmic agent. It increases the myocyte refractory period [14]. It prevents the negative effect of hyperkalemic depolarized arrest by polarizing the cell to some degree and reducing intracellular sodium and calcium influx [15]. The crystalloid del Nido solution is given with 20% volume blood additive. The blood has its effect in supporting aerobic metabolism, providing buffering capabilities and improving coronary perfusion during the delivery [16]. Some reports prove blood cardioplegia to be excellent in preserving myocardial metabolism and reducing ischemic stress along with reperfusion injury [17, 18]. What is important, the blood addition is the only source of calcium ions in the del Nido cardioplegia solution. This ensures that only a trace of calcium is given. The delivery temperature is 8–12°C. The hypothermia reduces metabolism and oxygen consumption [14, 19]. In 2012 Matte, who is a clinical perfusion coordinator at Boston Children’s Hospital, and del Nido himself described the aspects of using the cardioplegia at their institution in detail. The history, supporting theories and the protocols at the facility are discussed, which makes the publication a great reference for everyone who is interested in launching the del Nido cardioplegia protocol at their hospital [8]. Animal studies Del Nido cardioplegia has been deeply analyzed in both animal and human studies. In 2013 Govindapillai conducted a study in isolated rat hearts. He proved that del Nido cardioplegia is superior to blood cardioplegia in old hearts when spontaneous contractions during ischemia, troponin release and stroke work are taken into account [20]. The same author reported that single dose del Nido cardioplegia is superior to multidose del Nido cardioplegia in aged rat hearts (functional recovery was measured after 60 min of cardioplegic arrest) [21]. Pediatric patients The first clinical study referring to del Nido cardioplegia was conducted in Halifax by O’Brien in 2009. It proved that del Nido cardioplegia results in lower troponin T and better calcium management as compared to their institutional standard cardioplegia in pediatric patients [22]. Charette et al. carried out a clinical investigation in a group of 34 pediatric patients. Each patient had a cross-clamp time longer than 90 min and was given either single-dose del Nido cardioplegia or modified adult multidose cardioplegia solution. There were no significant differences between the groups in the risk adjustment for congenital heart surgery, cardiopulmonary bypass times, aortic cross camp times, weights or number of intraoperative exogenous blood units. The authors report that there were significant differences between the groups in the number of cardioplegia doses and in perioperative glucose levels [23]. Reports from pediatric cardiothoracic surgeons in North America described a single shot of del Nido cardioplegia solution to be the most commonly used cardioprotective strategy (38%), regardless of cross-clamp time [24]. Del Nido cardioplegia was compared with St Thomas cardioplegia in pediatric patients in a randomized trial. The study included 100 pediatric patients ≤ 12 years undergoing elective repair of ventricular septal defects and tetralogy of Fallot. A single dose of del Nido solution or 30-minute interval repeat St Thomas solution was administered. Apart from clinical parameters, myocardial biopsy was obtained to assess electron-microscopic ultrastructural changes. The cardiac index was on average 0.50 l/min/m2 higher in the del Nido group than in the St Thomas group at any time point (2, 6 and 24 h). Mechanical ventilation, intensive care unit stay and hospital stay were significantly lower in the del Nido group. The group also had lower troponin-I release at a 24-hour interval. Electron microscopic studies showed more myofibrillar disarray in the St Thomas solution group [25]. Another pediatric study that included those cardioplegic solutions in pediatric patients indicated a decrease in the rate of defibrillation post cross-clamp removal in all weight categories in the del Nido group [26]. The del Nido cardioplegia and modified St Thomas solution cardioplegia were compared in a randomized control trial in terms of inflammatory cytokine response and cardiac troponin I changes. The patients underwent tetralogy of Fallot surgery. No significant differences in TNF-α, IL-6 or IL-8 cytokines levels were reported. IL-10 level showed a moderately significant increase in the St Thomas solution group. Postoperative lactate level was significantly higher in the del Nido group. Differences in troponin levels were not detected. The authors concluded that anti-inflammatory cytokine response in the St Thomas solution group is significantly better than in the del Nido group, which may be due to shorter intervals of the St Thomas solution administration [27]. Adult patients The comparison between del Nido and St Thomas No. 2 solution was conducted in adult patients as well. The study included 100 patients who underwent coronary artery bypass grafting or double valve replacement. The aortic cross clamp and bypass times were shorter in the del Nido group. In this study the postoperative left ventricular ejection fraction was better preserved in the del Nido group [28]. Smigla et al. studied 47 consecutive adult patients (mean age: 40.9 years, range: 18–71), who received the del Nido cardioplegia for congenital surgery. According to the protocol, an additional dose of cardioplegia was given every 45 min. In patients who received a single dose (n = 19), the cross-clamp time was 49.8 ±18.8 min. The patients demonstrated no ventricular electrical activity while the aorta was cross-clamped. Post-operative ECHO showed that 94% had no change in ejection fraction from the pre-operative ECHO. However, 43% of patients needed inotropic support while leaving the OR. The average post-operative troponin T level was 1.86 ±2.9 µg/l [29]. Among propensity matched adult patients undergoing aortic or mitral surgery, who received either del Nido or Buckberg cardioplegia solution, troponin level and postoperative ejection fraction did not differ. Aortic clamp, bypass, and operating room times were shorter in the del Nido group. Peak glucose level and insulin requirements were also lower in this group [30]. Ramanathan retrospectively studied cases of 142 adult patients (valvular, aortic and bypass procedures) who received either del Nido or Buckberg cardioplegia. In this publication, fewer doses of cardioplegia and fewer defibrillations were noted in the del Nido group and there were no significant differences in incidence of postoperative events [31]. In a short-term analysis of adult patients who underwent aortic valve surgery (retrospective study) and were given either del Nido or conventional whole blood cardioplegia, mean cardiopulmonary bypass time and mean aortic cross-clamp time were significantly shorter in the del Nido group. Postoperative inotropic support was required in 20.4% of patients in the del Nido group and 24.1% of patients in the conventional group, with no significant difference. There was no significant difference in postoperative complications between the two groups [32]. The analysis of adult patients undergoing minimally invasive aortic valve surgery included 178 patients. Blood cardioplegia patients received both anterograde and retrograde cardioplegia in multiple doses while single-dose del Nido was delivered almost entirely anterogradely. The del Nido cardioplegia use was associated with decreased cardiopulmonary bypass time and aortic-cross clamp time. Maximal glucose level during cardiopulmonary bypass was lower in the del Nido group, while troponin T level and ejection fraction did not differ between the groups [33]. Another study reports a lower rate of ventricular fibrillation at unclamping and lower postoperative creatinine kinase-MB (CK-MB) values in the del Nido group with less postoperative use of intravenous insulin [34]. Coronary artery bypass surgery was proven to be safe with del Nido cardioplegia, as patients had similar results but required less defibrillation and blood transfusion when compared to blood cardioplegia [35]. Another study reported lower glucose levels during cardiopulmonary bypass [36]. Redo surgery is usually associated with longer cross-clamp and cardiopulmonary bypass times. Sorabella et al. investigated del Nido cardioplegia use in adult reoperative aortic valve surgery. This included 113 patients divided into del Nido and blood cardioplegia groups. There were no differences in cross-clamp time, bypass time, postoperative complication rate, or patient outcomes between groups [37]. The adequate myocardial protection of del Nido cardioplegia regardless of ventricular mass and myocardial ischemic time in adult cardiac surgical patients was reported by Kim et al. In this study, spontaneous defibrillation was achieved more frequently in the del Nido group when compared to blood cardioplegia groups. Peak level and serial changes of TnI were not significantly different between the two groups [38]. In a propensity matched trial (CABG + valve patients) Loberman et al. reported similar clamp and cardiopulmonary bypass time in both del Nido and whole blood cardioplegia groups. However, the del Nido group had higher CK-MB levels at 24 h, but lower incidence of postoperative atrial fibrillation [39]. Conclusions The literature is encouraging – the del Nido cardioplegia solution appears to be highly efficient in both myocardial protection and economic aspects. However, there are only a few randomized trials in pediatric patients and no randomized trials in adult patients. Most of them are retrospective or propensity matched, which makes their value limited. It is necessary to conduct a prospective, randomized trial to prove the hypothesis of feasibility or superiority of this cardioplegia over another in terms of myocardial protection. Disclosure Authors report no conflict of interest. ==== Refs References 1 Maxwell SRJ Lip GYH Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options Int J Cardiol 1997 58 95 117 9049675 2 Park JL Lucchesi BR Mechanisms of myocardial reperfusion injury Ann Thorac Surg 1998 68 1905 1912 3 Piper HM Meuter K Schäfer C Cellular mechanisms of ischemia-reperfusion injury Ann Thorac Surg 2003 75 S644 8 12607706 4 Bigelow WG Lindsay WK Greenwood WF Hypothermia; its possible role in cardiac su5. rgery: an investigation of factors governing survival in dogs at low body temperatures Ann Surg 1950 132 849 866 14771796 5 Melrose DG Dreyer B Bentall HH Baker JB Elective cardiac arrest Lancet 1955 269 21 22 14382605 6 Gerbode F Melrose D The use of potassium arrest in open cardiac surgery Am J Surg 1958 96 221 227 13559564 7 Hayashida N Isomura T Sato T Maruyama H Higashi T Arinaga K Aoyagi S Minimally diluted tepid blood cardioplegia Ann Thorac Surg 1998 65 615 621 9527182 8 Matte GS del Nido PJ History and use of del Nido cardioplegia solution at Boston Children’s Hospital J Extra Corpor Technol 2012 44 98 103 23198389 9 Powell WJ Jr DiBona DR Flores J Leaf A The protective effect of hyperosmotic mannitol in myocardial ischemia and necrosis Circulation 1976 54 603 615 963849 10 Iseri LT French JH Magnesium: nature’s physiologic calcium blocker Am Heart J 1984 108 188 193 6375330 11 Rebeyka IM Axford-Gatley RA Bush BG del Nido PJ Mickle DA Romaschin AD Wilson GJ Calcium paradox in an vivo model of multidose cardioplegia and moderate hypothermia. Prevention with diltiazem or trace calcium levels J Thorac Cardiovasc Surg 1990 99 475 483 2308365 12 Brown PS Jr Holland FW Parenteau GL Clark RE Magnesium ion is beneficial in hypothermic crystalloid cardioplegia Ann Thorac Surg 1991 51 359 366 1998412 13 Dobson GP Jones MW Adenosine and lidocaine: a new concept in nondepolarizing surgical myocardial arrest, protection, and preservation J Thorac Cardiovasc Surg 2004 127 794 805 15001909 14 Larach DR Solina AR Hensley FA Martin DE Cardiovascular drugs A Practical Approach to Cardiac Anesthesia 1995 2nd ed Boston Little, Brown and Company 32 95 15 O’Brien JD Howlett SE Burton HJ O’Blenes SB Litz DS Friesen CLH Pediatric cardioplegia strategy results in enhanced calcium metabolism and lower serum troponin T. Ann Thorac Surg 2009 87 1517 1524 16 Suaudeau J Shaffer B Dagget WM Austen WG Erdman AJ Role of procaine and washed red cells in the isolated dog heart perfused at 5 degrees C J Thorac Cardiovasc Surg 1982 84 886 896 7144221 17 Amark K Berggren H Bjork K Ekroth A Ekroth R Nilsson K Sunnegårdh J Blood cardioplegia provides superior protection in infant cardiac surgery Ann Thorac Surg 2005 80 989 994 16122471 18 Caputo M Modi P Imura H Pawade A Parry AJ Suleiman MS Angelini GD Cold blood versus cold crystalloid cardioplegia for repair of ventricular septal defects in pediatric heart surgery: a randomized controlled trial Ann Thorac Surg 2002 74 530 534 12173840 19 Bove EL Stammers AH Recovery of left ventricular function after hypothermic ischemia: age-related differences in the isolated working rabbit heart J Thorac Cardiovasc Surg 1986 91 115 122 3941554 20 Govindapillai A Hua R Rose R Friesen CH O’Blenes SB Protecting the aged heart during cardiac surgery: use of del Nido cardioplegia provides superior functional recovery in isolated hearts J Thorac Cardiovasc Surg 2013 146 940 948 23953721 21 Govindapillai A Hancock Friesen C O’Blenes SB Protecting the aged heart during cardiac surgery: single-dose del Nido cardioplegia is superior to multi-dose del Nido cardioplegia in isolated rat hearts Perfusion 2016 31 135 142 26034195 22 O’Brien JD Howlett SE Burton HJ O’Blenes SB Litz DS Friesen CL Pediatric cardioplegia strategy results in enhanced calcium metabolism and lower serum troponin T Ann Thorac Surg 2009 87 1517 1523 19379896 23 Charette K Gerrah R Quaegebeur J Chen J Riley D Mongero L Corda R Bacha E Single dose myocardial protection technique utilizing del Nido cardioplegia solution during congenital heart surgery procedures Perfusion 2012 27 98 103 22005886 24 Kotani Y Tweddell J Gruber P Pizarro C Austin EH 3rd Woods RK Gruenwald C Caldarone CA Current cardioplegia practice in pediatric cardiac surgery: a North American multiinstitutional survey Ann Thorac Surg 2013 96 923 929 23915588 25 Talwar S Bhoje A Sreenivas V Makhija N Aarav S Choudhary SK Airan B Comparison of del Nido and St Thomas cardioplegia solutions in pediatric patients: a prospective randomized clinical trial Semin Thorac Cardiovasc Surg 2017 29 366 374 29055711 26 Buel ST Striker CW O’Brien JE del Nido versus St. Thomas cardioplegia solutions: a single-center retrospective analysis of post cross-clamp defibrillation rates J Extra Corpor Technol 2016 48 67 70 27578896 27 Gorjipour F Dehaki MG Totonchi Z Hajimiresmaiel SJ Azarfarin R Pazoki-Toroudi H Mahdavi M Korbi M Dehaki MG Soltani B Gorjipour F Inflammatory cytokine response and cardiac troponin I changes in cardiopulmonary bypass using two cardioplegia solutions; del Nido and modified St. Thomas’: a randomized controlled trial Perfusion 2017 32 394 402 28152655 28 Mishra P Jadhav RB Mohapatra CK Khandekar J Raut C Ammannaya GK Seth HS Singh J Shah V Comparison of del Nido cardioplegia and St. Thomas Hospital solution – two types of cardioplegia in adult cardiac surgery Kardiochir Torakochir Pol 2016 13 295 299 29 Smigla G Jaquiss R Walczak R Bonadonna D Kaemmer D Schwimer C Lodge A Assessing the safety of del Nido cardioplegia solution in adult congenital cases Perfusion 2014 29 554 558 25009226 30 Mick SL Robich MP Houghtaling PL Gillinov AM Soltesz EG Johnston DR Blackstone EH Sabik JF 3rd del Nido versus Buckberg cardioplegia in adult isolated valve surgery J Thorac Cardiovasc Surg 2015 149 626 634 25483897 31 Ramanathan R Parrish DW Armour TK Brinster DR Use of del Nido cardioplegia in adult cardiac surgery Thorac Cardiovasc Surg 2015 63 624 627 25742549 32 Ota T Yerebakan H Neely RC Mongero L George I Takayama H Williams MR Naka Y Argenziano M Bacha E Smith CR Stewart AS Short-term outcomes in adult cardiac surgery in the use of del Nido cardioplegia solution Perfusion 2016 31 27 33 26228274 33 Ziazadeh D Mater R Himelhoch B Borgman A Parker JL Willekes CL Timek TA Single dose Del Nido cardioplegia in minimally invasive aortic valve surgery Semin Thorac Cardiovasc Surg 2017 11 2 10.1053/j.semtcvs.2017.10.001 34 Vistarini N Laliberté E Beauchamp P Bouhout I Lamarche Y Cartier R Carrier M Perrault L Bouchard D El-Hamamsy I Pellerin M Demers P Del Nido cardioplegia in the setting of minimally invasive aortic valve surgery Perfusion 2017 32 112 117 27469246 35 Guajardo Salinas GE Nutt R Rodriguez-Araujo G Del Nido cardioplegia in low risk adults undergoing first time coronary artery bypass surgery Perfusion 2017 32 68 73 27451052 36 Timek T Willekes C Hulme O Himelhoch B Nadeau D Borgman A Clousing J Kanten D Wagner J Propensity matched analysis of del Nido cardioplegia in adult coronary artery bypass grafting: initial experience with 100 consecutive patients Ann Thorac Surg 2016 101 2237 2241 27016843 37 Sorabella RA Akashi H Yerebakan H Najjar M Mannan A Williams MR Smith CR George I Myocardial protection using del Nido cardioplegia solution in adult reoperative aortic valve surgery J Card Surg 2014 29 445 449 24861160 38 Kim JS Jeong JH Moon SJ Ahn H Hwang HY Sufficient myocardial protection of del Nido cardioplegia regardless of ventricular mass and myocardial ischemic time in adult cardiac surgical patients J Thorac Dis 2016 8 2004 2010 27621853 39 Loberman D Neely RC Fitzgerald D Modified del Nido cardioplegia in adult cardiac surgery: safety and efficacy J Cardiol Curr Res 2014 1 00042